Essence semaglutide: the facts behind the name

Is "essence semaglutide" a real medicine, or just a description?

It is a description. Semaglutide is the molecule; "essence semaglutide" is informal shorthand that has spread through wellness content and social media to mean semaglutide-based weight-loss treatment in its broadest sense. No medicine is licensed under that name in the UK. If you have seen the phrase on a product listing, a social-media post, or an unofficial seller's site, treat that as a warning sign rather than a product category.

The licensed semaglutide products for weight management in the UK are Wegovy (injection) and, as of June 2026, Wegovy tablets. Both are manufactured by Novo Nordisk and are available only on prescription after a clinical assessment. Our semaglutide guide covers the licensed options in detail, including the difference between the injection and the new oral format.

Ozempic is also semaglutide, but its UK licence covers type 2 diabetes management, not weight loss. Prescribing it for weight loss outside its licence is a decision that carries clinical and legal weight, it is not a simple swap. The NHS is clear on this distinction, and so is the NHS medicines page on semaglutide.

How does semaglutide produce weight loss?

Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1 is a hormone your gut releases after eating; it tells the brain you are full, prompts the pancreas to release insulin, and slows gastric emptying so food stays in the stomach longer. Semaglutide mimics this signal at a sustained, amplified level throughout the week from a single dose.

The practical effect for most people is a meaningful reduction in appetite. Portions that previously felt normal start to feel large. Cravings, particularly for calorie-dense foods, often ease. This is not a stimulant effect, there is no jitteriness or raised heart rate as the mechanism. The appetite change tends to be quieter and more gradual, which is why most people only notice the full effect once they have been on a therapeutic dose for several weeks.

Treatment starts at a low dose to give the body time to adjust, then escalates in stages set by the prescriber. The dosing schedule for Wegovy runs from 0.25 mg up to 2.4 mg weekly, with semaglutide 1 mg representing one of the earlier steps patients pass through on the way to a therapeutic maintenance dose. Dose decisions always sit with the prescriber, not the patient.

What does the clinical evidence actually show?

The headline figure comes from STEP 1, a 68-week randomised trial of semaglutide 2.4 mg, the dose studied in the pivotal weight-loss trials, in adults with obesity or overweight and at least one weight-related condition: participants lost an average of around 15% of body weight alongside a reduced-calorie diet and increased physical activity. The paper was published in the New England Journal of Medicine and formed the backbone of NICE's appraisal for Wegovy.

The 7.2 mg dose, approved by the MHRA in April 2026, produced around 20.7% average weight loss over 72 weeks in trials, which narrows the gap with tirzepatide at its highest dose. Comparing the weight-loss medicines licensed in the UK is worth doing before deciding which is the right fit clinically, though that decision ultimately belongs to a prescriber who knows your history.

These are population averages. Individual results vary depending on starting weight, adherence to lifestyle changes, dose reached, and how someone's biology responds. Clinical trials do not guarantee personal outcomes, and any source claiming they do should be read with caution.

What should you know before starting semaglutide treatment?

Side effects are mostly gastrointestinal: nausea, loose stools, constipation, indigestion, and burping are the most commonly reported. They tend to peak in the days after a dose increase and ease as the body settles. Staying well hydrated and eating smaller, lower-fat meals helps most people manage them.

Semaglutide is not suitable during pregnancy, breastfeeding, or when actively trying to conceive. It is not licensed for under-18s. People with a history of pancreatitis, certain thyroid conditions, or specific gastrointestinal disorders should discuss their history with a prescriber before starting. Severe, persistent stomach pain that spreads to the back (with or without vomiting) needs prompt medical attention; the MHRA highlighted acute pancreatitis as a known risk in a Drug Safety Update issued in January 2026.

There is also a contraception point worth knowing: women taking oral contraceptive pills alongside tirzepatide (a different GLP-1 medicine) are advised to add a non-oral method for the first four weeks of treatment and after each dose increase. The NHS notes this effect has not been established for semaglutide in the same way, but it is worth raising with your prescriber regardless. Questions about timing (whether to start before a holiday, after a particularly stressful patch, or on a specific week) are exactly the kind of thing to bring to a consultation rather than guess at.

For a fuller look at what the consultation involves, our Wegovy pricing and treatment page sets out what is included in a private prescription. If you want to speak to the clinical team directly, our clinical lead's profile is on the site, and our FAQs page covers common questions we hear every week.

When you are ready, starting a free consultation is the straightforward next step, a GPhC-registered prescriber reviews your answers the same day, with no algorithm standing between you and a real clinical decision.